According to InvestingPro analysis, GSK maintains a "GREAT" financial health score, positioning it well for continued pharmaceutical innovation. If approved, depemokimab would be the first ultra ...

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, depemokimab, for treating adults with chronic rhinosinusitis with ...

Depemokimab, GSK’s long-acting, anti-interleukin (IL)-5 monoclonal antibody (mAB), is currently under review as an add-on maintenance treatment for asthma in paediatric ...

Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being ...

FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements.

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials.. The ANCHOR ...

GSK's depemokimab met key endpoints in phase 3 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), showing promise in reducing nasal polyp growth and obstruction. Full results to be ...

GSK is continuing to tout depemokimab as one of its 12 potential blockbuster launches of the coming years, with the asthma drug expected to generate peak-year sales of 3 billion pounds sterling ...

On 20 May 2025 at the American Thoracic Society (ATS) International Conference in San Francisco, a poster presentation by GlaxoSmithKline (GSK) provided insight into the therapeutic benefit of ...

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, depemokimab, for treating adults with chronic rhinosinusitis with ...

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, depemokimab, for treating adults with chronic rhinosinusitis with ...